Caribou brings in $11m for CRISPR tech

Closely-watched start-up Caribou Biosciences announced 02 April that it has brought in $11m in Series A round financing through a group of deep-pocketed investors, including European pharma giant Novartis.

The biotech is a developer of CRISPR-cas9 technology, a type of gene editing that has the oncology world abuzz.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip